Telix Pharmaceuticals Ltd. ( (AU:TLX) ) has shared an announcement.
Telix Pharmaceuticals Limited has announced that the recent U.S. government trade tariffs will not materially impact its business or supply chain. This is due to its extensive U.S.-based manufacturing and distribution infrastructure and the exemption of pharmaceutical products from these tariffs. Additionally, Telix is unaffected by Chinese export controls on rare earth elements, as these are not used in its products. The company remains on track with its new drug applications, despite changes at the FDA, and plans to continue its ‘just-in-time’ production approach for radiopharmaceuticals.
More about Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Headquartered in Melbourne, Australia, Telix operates internationally in the United States, Brazil, Canada, Europe, and Japan. The company is working on a portfolio of clinical and commercial stage products targeting significant unmet medical needs in oncology and rare diseases.
YTD Price Performance: -4.35%
Average Trading Volume: 5,340
Technical Sentiment Signal: Sell
Current Market Cap: $4.82B
For an in-depth examination of TLX stock, go to TipRanks’ Stock Analysis page.